Market Place
Sourcing Support
Sangamo`s FDA Clearance for ST-503 in Small Fiber Neuropathy
19 Nov 2024 //
BUSINESSWIRE
Sangamo Therapeutics Reports Q3 2024 Results & Business Highlights
12 Nov 2024 //
BUSINESSWIRE
Sangamo Therapeutics Announces Q3 2024 Conference Call and webcast
04 Nov 2024 //
BUSINESSWIRE
Sangamo slashes time to market for Fabry gene therapy
23 Oct 2024 //
FIERCE BIOTECH
Sangamo secures $50M upfront in neurodegenerative pact with Roche`s Genentech
07 Aug 2024 //
FEIRCE BIOTECH
Sangamo secures $50M upfront in neurodegenerative pact with Roche`s Genentech
06 Aug 2024 //
FIERCE BIOTECH
Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast
30 Jul 2024 //
BUSINESSWIRE
Sangamo Reports Positive Phase 3 Results Of Pfizer`s Hemophilia A Therapy
24 Jul 2024 //
BUSINESSWIRE
Sangamo Next-Gen Integrase For Large Genome Editing
09 May 2024 //
BUSINESSWIRE
Sangamo Therapeutics Q1 2024 Financials, Business Highlights
09 May 2024 //
BUSINESSWIRE
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
02 May 2024 //
BUSINESSWIRE
Sangamo`s Neuro Gene Editing, Delivery Platforms At ASGCT
22 Apr 2024 //
BUSINESSWIRE
Sangamo Announces Pricing of $24.0 Million Registered Direct Offering
22 Mar 2024 //
BUSINESSWIRE
Sangamo Announces Data From Novel Proprietary Neurotropic AAV Capsid
13 Mar 2024 //
BUSINESSWIRE
Sangamo Reports Fourth Quarter and Full Year 2023 Financial Results
13 Mar 2024 //
BUSINESSWIRE
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call
12 Mar 2024 //
BUSINESSWIRE
Sangamo Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease
05 Feb 2024 //
BUSINESSWIRE
Sangamo lays off 160+ staffers
02 Nov 2023 //
ENDPTS
Rani and Sangamo jettison staff, assets to keep afloat next year
02 Nov 2023 //
FIERCE BIOTECH
Sangamo Therapeutics Reports Third Quarter 2023 Financial Results
01 Nov 2023 //
BUSINESSWIRE
Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
25 Oct 2023 //
BUSINESSWIRE
Sangamo to Present Data Showcasing Its Epigenetic Regulation for Neurology
24 Oct 2023 //
BUSINESSWIRE
Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
20 Sep 2023 //
BUSINESSWIRE
Sangamo Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
BUSINESSWIRE
Sangamo Therapeutics Announces Second Quarter 2023 Conference Call and Webcast
01 Aug 2023 //
BUSINESSWIRE
Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement
20 Jul 2023 //
BUSINESSWIRE
Lilly taps Sangamo to explore AAV capsids for neurological targets
18 Jul 2023 //
PRESS RELEASE
Sangamo & Voyager Enter License Agreement for Epigenetic Regulation
29 Jun 2023 //
BUSINESSWIRE
Sangamo Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec
22 May 2023 //
BUSINESSWIRE
Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as CMO
16 May 2023 //
BUSINESSWIRE
Sangamo to Present Pre-clinical Data From Its Genomic Engineering Platform ASGCT
02 May 2023 //
BUSINESSWIRE
Sangamo Announces Strategic Update and Reports Preliminary1Q FYR 2023
27 Apr 2023 //
BUSINESSWIRE
Sangamo Therapeutics Announces First Quarter 2023 Conference Call and Webcast
19 Apr 2023 //
BUSINESSWIRE
Novartis, Biogen Scrap Gene Regulation Partnerships with Sangamo
21 Mar 2023 //
BIOSPACE
Sangamo scraps public offering ‘after evaluating market conditions’
03 Mar 2023 //
ENDPTS
Sangamo, joining other rivals, shelves sickle cell therapy
23 Feb 2023 //
FIERCE BIOTECH
Sangamo Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast
21 Feb 2023 //
BUSINESSWIRE
Sickle cell cure will be cost-effective if health disparities considered
15 Dec 2022 //
REUTERS
Sangamo Therapeutics Reports Recent Business Highlights and 3Q FYR
03 Nov 2022 //
PRESS RELEASE
Sangamo Therapeutics Announces Third Quarter 2022 Conference Call and Webcast
27 Oct 2022 //
BUSINESSWIRE
Sangamo gives update on early-stage Fabry program, enters trial expansion phase
13 Oct 2022 //
ENDPTS
Pfizer, Sangamo set to resume gene therapy study after safety delay
24 Sep 2022 //
BIOPHARMADIVE
Sangamo Therapeutics Announces Updated Preliminary Ph 1/2 Data in Fabry Disease
30 Aug 2022 //
BUSINESSWIRE
Sangamo’s Fabry disease gene therapy appears to be working so far in patients
30 Aug 2022 //
ENDPTS
Sangamo Therapeutics Reports Second Quarter 2022 Financial Results
04 Aug 2022 //
BUSINESSWIRE
Sangamo Therapeutics Announces Second Quarter 2022 Conference Call and Webcast
28 Jul 2022 //
BUSINESSWIRE
European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics
21 Jul 2022 //
BUSINESSWIRE
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
01 Jun 2022 //
BUSINESSWIRE
Sangamo Therapeutics Reports First Quarter 2022 Financial Results
05 May 2022 //
BUSINESSWIRE
Sangamo Tx to Present Data From Its Next-Generation Technologies at 2022 ASGCT
02 May 2022 //
BUSINESSWIRE
Sangamo Therapeutics Announces First Quarter 2022 Conference Call and Webcast
28 Apr 2022 //
BUSINESSWIRE
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
21 Apr 2022 //
BUSINESSWIRE
Sangamo Begins Dosing in Phase 1/2 Study of Investigational TX200
29 Mar 2022 //
BUSINESSWIRE
Sangamo Tx Announces Participation at Upcoming Investor Conferences
28 Feb 2022 //
BUSINESSWIRE
Sangamo Tx Reports Q4 and Full Year 2021 Financial Results
24 Feb 2022 //
BUSINESSWIRE
Sangamo Therapeutics Announces Q4 and Full Year 2021 Call and Webcast
17 Feb 2022 //
BUSINESSWIRE
Sangamo Updates Prelim Phase 1/2 Data Showing Tolerability & Sustained Activity
07 Feb 2022 //
BUSINESSWIRE
Senti Bio, Sangamo alum Lee joins Lyell as CSO
01 Feb 2022 //
BIOCENTURY
Sanofi cuts ties with Sangamo, sharpening focus on `off-the-shelf` cell therapy
07 Jan 2022 //
BIOPHARMADIVE
